ࡱ >
\ p None B a = c @ = Z ?N*8 X" 1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial General ` Table_2 _: / Sub-type Description Pathway% Potentially relevant therapies% Relevant histological subtypes- Strength of evidence for clinical use* 4.1 c-MET overexpression c-MET] c-MET inhibitors, Dual Met/VEGFR2 inhibitors, ALK/MET inhibitors, c-MET monoclonal antibodies. Adenocarcinoma, small cell carcinoma, squamous Medium 4.2 c-MET mutations] c-MET inhibitors, dual Met/VEGFR2 inhibitors, ALK/MET inhibitors, c-MET monoclonal antibodies: Adenocarcinoma, squamous, large cell, small cell carcinoma Low 5.1 PI3KCA amplification, mutations AKT/PI3K PI3K, AKT, mTOR inhibitors Adenocarcinoma 5.2 PTEN deletions/methylation 6.1 VEGFR overexpression VEGFR VEGFR inhibitors Small cell carcinoma 6.2 Bcl-2 overexpression P53/BCL BCL-2 Inhibitors 7.1 ROS1 translocation ROS-1 ROS1 inhibitors Adenocarcinoma (1.5%) 8.1 Epigenetic alterations<